Welcome to SYNIMMUNE

SYNIMMUNE GmbH is a biotechnology company dedicated to the development of innovative and effective mono- and bispecific anti-tumor antibodies for the treatment of patients suffering from life-threatening diseases, with a focus on orphan hematopoietic malignancies. SYNIMMUNE’s lead product candidate is the antibody FLYSYN, which is currently in a first-in-human phase I clinical study in acute myeloid leukemia (AML). SYNIMMUNE GmbH is a spin-off of the Department of Immunology of the University of Tuebingen. The Company is financed by grants from the German Ministry of Education and Research (BMBF) within its GO-Bio program as well as investments by the German KfW and private equity.

For AML Patients interested in our clinical study: http://www.uniklinikum-tuebingen-studien.de/aml-studie

 

 

PRESS RELEASE

 

Tuebingen, 30 May 2017: SYNIMMUNE GmbH Initiates First-in-Human Study of Fc-optimized Antibody FLYSYN for the Treatment of Acute Myeloid Leukemia

 

DOWNLOAD

Contact:

Synimmune GmbH:

Dr. Martin Steiner

CEO

+49 7071 770 8382

steiner[at]synimmune.de